Mersana Therapeutics, Inc. ( NASDAQ:MRSN ) missed earnings with its latest second-quarter results, disappointing...
Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -11.11% and 72.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Dose escalation advancing in Phase 1 clinical trials of both XMT-1660 and XMT-2056 Continue to expect to announce initial XMT-1660 clinical data and initiate expansion in the second half of 2024 Capital resources expected to support current operating plan commitments into 2026 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeli